NCT00401271已完成2 期
A Phase II Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Four Oral Doses of OPC-67683 in Patients With Uncomplicated, Smear-Positive, Pulmonary Tuberculosis
Otsuka Frankfurt Research Institute GmbH6 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2006年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
- 试验地点
- 6
- 主要终点
- TB bacterial load in sputum measured as colony forming units
研究概览
简要总结
The purpose of this trial is to evaluate the safety, efficacy and pharmacokinetics of 100mg, 200mg , 300mg and 400mg once daily of OPC-67683, administered orally for 14 consecutive days, in patients with uncomplicated, smear-positive pulmonary TB.
The four OPC-67683 treatment groups will comprise 12 patients each and the one standard therapy (Rifafour e-275) group six patients.
Trial 242-06-101 is an exploratory and not a confirmatory trial and as such no hypothesis will be tested statistically.
The control group, six patients treated with Rifafour, will serve as an control to confirm the microbiological assessments during the trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written, informed consent prior to all trial-related procedures.
- •Male and female patients aged between 18 and 64 years, inclusive.
- •Newly diagnosed, previously untreated, uncomplicated, smear positive, pulmonary TB.
- •A chest X-ray finding compatible with TB.
- •Sputum positive on direct microscopy for acid-fast bacilli (AFB) (at least 1+).
- •Able to produce an adequate volume of sputum (10mL or more estimated overnight production).
- •Female patients of childbearing potential must demonstrate a negative pregnancy test result. Furthermore they must agree to use a highly effective method of contraception.
- •Male patients must agree to use an adequate method of contraception.
排除标准
- •Poor general condition where no delay in treatment can be tolerated or where immediate hospital admission is warranted.
- •Rifampicin-resistant bacteria detected in the sputum susceptibility testing at Screening.
- •Treatment received with any drug active against M. tuberculosis within the 3 months prior to Screening.
- •History of allergy to any nitro-imidazole derivates, rifamycin derivatives, isoniazid derivatives, pyrazinamide or ethambutol.
- •Clinical evidence of severe extrathoracic TB (miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis).
- •Evidence of pulmonary silicosis, lung fibrosis, or other lung condition considered as severe by the investigator (other than TB).
- •Presence of chronic obstructive pulmonary disease or asthma.
- •Any clinically relevant concomitant conditions or renal impairment characterized by serum creatinine levels >= 1.5xULN or hepatic impairment or alcohol abuse characterized by ALT and/or aspartate transferase (AST) levels 3xULN and/or gamma-glutamyl transpeptidase (GGT) levels 3xULN of the laboratory reference range.
- •Known or suspected alcohol or drug abuse, that is, abuse sufficient enough to compromise the safety or cooperation of the patient, in the opinion of the investigator, and as evident by a positive urine drug screen.
- •Neuropathy, psychosis or epilepsy.
- •Clinically relevant changes in the ECG such as atrioventricular (AV) block, prolongation of the QRS complex >120 milliseconds (in both male and female patients), or QTcB interval >430 milliseconds in male patients and >450 milliseconds in female patients. Family history of long QT syndromes and/or Torsade de Pointes.
- •History of or current clinically relevant cardiovascular disorder such as hypokalaemia, heart failure, coronary heart disease, hypertension, arrhythmia or symptom strongly suggestive of such a problem (for example, syncope or palpitations), tachyarrhythmia or status after myocardial infarction.
- •Known bleeding disorders or family history of bleeding disorders.
- •Diabetes treated with insulin.
- •Evidence of clinically significant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied).
- •Any diseases or conditions in which the use of rifampicin, isoniazid, pyrazinamide or ethambutol is contra-indicated.
- •Any disease or conditions in which any of the medicinal products listed in the protocol, is used. Treatment received with quinolones and prednisolone within 3 months prior to Screening.
- •Administration of an IMP within 1 month prior to Screening.
- •Pregnancy, breast-feeding, or planning to conceive or father a child within the timeframe described in the informed consent form.
- •Recent use of methadone, benzodiazepines, cocaine, amphetamine/metamphetamine, tetrahydrocannabinol, barbiturates, tricyclic antidepressants, and opiates as determined by a urine drug screen.
- •Helper/inducer T lymphocyte (CD4 cell) count of <=350x106/L.
- •Use of antiretroviral therapy.
结局指标
主要结局
TB bacterial load in sputum measured as colony forming units
次要结局
- Tme to culture positivity
- Early Bactericidal Activity (EBA)
- Slope 0-14
研究者
研究点 (6)
Loading locations...
相似试验
招募中
2 期
A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .Renal AnemiaNCT05629598Angde Biotech Pharmaceutical Co., Ltd.150
已完成
2 期
A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungAdenocarcinomaNCT02875340ValiSeek Limited8
进行中（未招募）
1 期
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung CancerNon-small Cell Lung CancerNCT06114511Sichuan Baili Pharmaceutical Co., Ltd.78
已完成
1 期
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic MalignanciesHematologic NeoplasmsNCT02329847Janssen Research & Development, LLC144
招募中
2 期
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3GIgA NephropathyLupus Nephritis (LN)C3 (Complement Component 3) GlomerulopathyNCT06419205Akebia Therapeutics30